Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

NCT02858453 is registered in ClinicalTrials.gov with Aquinox Pharmaceuticals (Canada) Inc. as lead sponsor.

NCT NCT02858453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2016
Completion date
February 29, 2020
Enrollment
433 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

bladder pain syndrome, chronic interstitial cystitis, interstitial cystitis, painful bladder syndrome